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Background: Erythropoietin deficiency is the major cause of anemia in hemodialysis patients. Although continuous
erythropoietin receptor activator (CERA) has a long half-life and once-monthly administration is recommended, the
optimal interval to achieve the greatest efficacy is not known.
Methods: In 44 hemodialysis patients, CERA was administered at an interval of once every 2 weeks (Q2W) and
4 weeks (Q4W) consecutively and reticulocyte counts and hemoglobin levels were compared prospectively. In six
patients with CERA 100 μg/4 weeks, CERA intervals were further changed to 1 week (Q1W).
Results: Mean reticulocyte counts were higher during Q2W than Q4W (41.5 ± 10.7 and 36.4 ± 8.8 × 103/μL, respectively,
p < 0.0001), and hemoglobin levels decreased during Q4W. These results were irrespective of the CERA dose (50, 100,
and 150 μg/4 weeks). In six patients with CERA 100 μg/4 weeks, although not significant, reticulocyte counts were
higher during Q2W and Q1W than Q4W and hemoglobin levels were highest during Q1W (p < 0.05).
Conclusions: In our hemodialysis patients, an interval of CERA shorter than 4 weeks appeared to be more effective for
the treatment of anemia.
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Anemia is common in patients with chronic renal
failure. Its causes include erythropoietin (EPO) defi-
ciency, iron deficiency, inflammation, hyperparathyroid-
ism, and in hemodialysis patients, blood loss related to
the hemodialysis procedure. Although all these factors
contribute to the anemia of hemodialysis patients, EPO
deficiency is thought to be the major one. Anemia is
associated with poorer patient survival [1, 2] and quality
of life [3]. After the introduction of erythropoietin-
stimulating agents (ESAs), the management of renal
anemia has improved and has been associated with
improved survival of hemodialysis patients [4].* Correspondence: dai-clinic@m2.spacelan.ne.jp
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(http://creativecommons.org/publicdomain/zeTraditional ESAs have relatively short intravenous
half-lives (epoetin alfa and beta, 7–9 h) [5] and require
frequent administration. Continuous erythropoietin re-
ceptor activator (CERA) has a long half-life (134 and
139 h following intravenous and subcutaneous adminis-
tration, respectively) [6] and is administered at wider
intervals than epoetin or darbepoetin alfa for renal
anemia in patients with chronic kidney disease. Al-
though conversion to CERA with intervals of once every
2 weeks (Q2W) or 4 weeks (Q4W) from other ESAs is
achieved safely in hemodialysis patients and once-
monthly administration is recommended in Japan, the
optimal interval of CERA administration is not known.
Recently, it is reported that more continuous erythropoi-
esis was achieved with a Q2W administration of CERA
than Q4W [7], and Q2W administration of CERA is
more effective than Q4W to achieve target hemoglobin
(Hb) levels [8]. Although we also reported more effectivele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Daimon et al. Renal Replacement Therapy  (2016) 2:58 Page 2 of 8erythropoiesis of CERA by Q2W than Q4W, the fluctu-
ation of Hb levels during Q4W is greater than that
during Q2W [9], which makes it difficult to compare
the true effect of the interval of CERA administration
on Hb levels.
Usually the responsiveness to ESAs in hemodialysis
patients is defined by the ESA dose and Hb levels [10],
with low Hb levels at the same dose of ESAs meaning
hypo-responsiveness to ESAs. This “responsiveness” is
not equal to “red blood cell (RBC) production”. In the
absence of considerable blood loss, Hb levels are affected
not only by the RBC production rate but also by the
death rate, which means RBC lifespan. In hemodialysis
patients, shortened and high interindividual variability of
RBC lifespan is reported [11] and may have a substantial
impact on Hb levels, which has been largely neglected.
For these reasons, Hb levels alone are not suitable to
evaluate the erythropoietic effect of CERA according to
administration interval, which prompted us to compare
also reticulocyte counts during 4-, 2-, and 1-week inter-
vals of CERA administration.
Methods
This prospective study focused on 44 hemodialysis pa-
tients in Daimon Clinic for Internal Medicine, Nephrol-
ogy and Dialysis, whose Hb levels were controlled
between 9 and 12 g/dL without changes in the CERA
dose administered by Q2W for more than 3 months.
Table 1 shows patient characteristics at baseline. Hb was
controlled within a narrow range (10.9 ± 0.8 g/dL) under
the same dosage of CERA administered by Q2W (50 μg
per 4 weeks, N = 25; 100 μg, N = 13; and 150 μg, N = 6).
Serum levels of hepcidin-25 were measured using a
liquid chromatography-tandem mass spectrometric
method [12]. Reticulocyte counts and Hb levels were
evaluated every week for 4 weeks, and then CERA ad-
ministration intervals were changed to 4 weeks (same
dosage per 4 weeks). After the 4-week wash-out period,
weekly reticulocyte counts and Hb levels were evaluated
again for 4 weeks. To compare the erythropoietic effect
of CERA by Q2W and Q4W, we evaluated the mean re-
ticulocyte counts of the first hemodialysis session of the
week during the 4 weeks of the evaluation period.
In 6 of 13 patients, 100 μg of CERA was adminis-
tered every 4 weeks and Hb levels were between 9
and 12 g/dL at the end of the above study, after
which CERA intervals were further changed to 1 week
(Q1W) (25 μg of CERA every week) and reticulocyte
counts and Hb levels were evaluated prospectively for
a further 8 weeks (Fig. 1).
As a rule, iron has been administered orally in our
clinic, with intravenous iron not administered during the
study period. In 28 of the 44 patients, oral iron had been
prescribed every day at least 3 months before the study(sodium ferrous citrate, N = 21; ferric citrate, N = 7, re-
spectively) and did not change during the study period.
This study was approved by the local ethics committee
(issue 2014-A1 at Daimon Clinic for Internal Medicine,
Nephrology and Dialysis), and written informed consent
was obtained from all patients.
Statistical analyses
Data were expressed as the mean ± SD. Paired and un-
paired t tests and chi square test were used to compare
the data. Statistical significance is defined as p less than
0.05.
Results
Figure 2 shows the weekly changes of reticulocyte
counts during CERA administration by Q2W and Q4W.
Three groups by CERA dose (50, 100, and 150 μg/4W)
showed a similar pattern of reticulocyte count changes.
As shown in Table 2, mean reticulocyte counts were
higher during Q2W than during Q4W irrespective of
CERA dose (p < 0.005, p < 0.05, and p < 0.05 for CERA
50, 100, and 150 μg/4W, respectively). Although Hb
levels were stable during the period of CERA by Q2W,
after the switch to Q4W, Hb levels showed a tendency
to decrease (Fig. 3).
In six patients with CERA 100 μg per 4 weeks who
were switched to Q1W further, as shown in Fig. 4, re-
ticulocyte counts were maximal (50–56 × 103/μL)
around 2 weeks after the switch to Q1W and Hb in-
creased gradually and reached a plateau 6 weeks after
the switch to Q1W. Mean reticulocyte counts during the
evaluation periods of Q4W, Q2W, and Q1W were 34.6
± 22.3, 41.9 ± 19.9, and 38.3 ± 10.8 × 103/μL, respectively
(p = n.s.). Mean Hb levels were 11.1 ± 0.9, 11.2 ± 1.3, and
12.0 ± 2.2 g/dL, respectively (p < 0.05 Q1W vs. Q2W and
Q1W vs. Q4W). Serum iron and ferritin levels at the
switch to Q1W were 105.3 ± 42.5 μg/dL and 145.3 ±
81.5 ng/mL, and 8 weeks later, 75.3 ± 40.9 μg/dL (p = n.s.)
and 91.6 ± 109.6 ng/mL (p < 0.05), respectively.
Discussion
EPO deficiency is the major cause of anemia in patients
with chronic renal failure. ESAs correct anemia by bind-
ing to erythropoietin receptors expressed on progenitor
cells in the bone marrow which leads to inhibition of cell
apoptosis and enhancement of proliferation and differ-
entiation [13]. The stimulated progenitor cells differenti-
ate to erythroblasts, then mature to reticulocytes and
finally to RBCs. Hematopoiesis by ESA administration
influences iron metabolism. Although the precise mech-
anisms are not clear, in hemodialysis patients, ESA
administration exerts a biphasic pattern of serum
hepcidin-25 levels; early upregulation followed by late
downregulation [14], and low serum hepcidin levels
Table 1 Patient characteristics at baseline
CERA dosage
(μg/4 weeks)














Fe (μg/dL) Ferritin (ng/mL) Hepcidin-25
(ng/mL)
50 (N = 25) 16 (64.0) 70.0 ± 11.3
(35–87)






100 (N = 13) 9 (69.2) 70.6 ± 7.7
(53–85)






150 (N = 6) 5 (83.3) 69.0 ± 9.3
(51–75)






All (N = 44) 30 (68.2) 70.0 ± 9.9
(35–87)






Variables are represented as mean ± standard deviation













Fig. 1 Study design schema
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serum ferritin levels. The degree of iron utilization and
recruitment to the hematopoietic system seems to differ
according to the type of ESAs [14–16] and interval of
dosing [7, 8]. Transient reduction of serum hepcidin and
ferritin levels induced by CERA administration reach aFig. 2 Reticulocyte counts according to the dosage of CERAmaximum around 1 week after dosing and return to
pre-administration levels by 4 weeks, with this being the
rationale of the once-monthly administration of CERA.
These transient changes of serum ferritin and hepcidin
levels induced by CERA are considered to be due to sus-
tained stimulation of erythropoiesis by CERA which lasts
Table 2 Mean reticulocyte counts during the administration of








50 (N = 25) 40.7 ± 10.0 36.2 ± 9.9 <0.005
100 (N = 13) 41.6 ± 12.5 35.8 ± 7.8 <0.05
150 (N = 6) 44.7 ± 10.8 38.4 ± 7.0 <0.05
All (N = 44) 41.5 ± 10.7 36.4 ± 8.8 <0.0001
Variables are represented as mean ± standard deviation
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CERA has a long half-life, and once-monthly administra-
tion of CERA is safe and reported to save up to 144
injections per hemodialysis patient per year compared
with three times weekly dosing [17], it is reported that
Q2W administration of CERA is more effective than
Q4W to achieve target Hb levels [7, 8, 17], which made
us wonder what would be the optimal interval of CERA
administration from the standpoint of efficacy.
As shown in Table 2, our study demonstrated higher
mean reticulocyte counts in patients with CERA admin-
istered at Q2W than Q4W. In six patients, we further
evaluated Hb levels and reticulocyte counts after CERA
was administered by Q2W, Q4W, and Q1W sequentially
(Fig. 4). During Q1W, Hb increased gradually and
reached a higher level than that during Q2W and Q4W.
Reticulocyte counts were highest in the first 2–4 weeks
during the period of Q1W and persisted around theFig. 3 Hemoglobin levels according to the dosage of CERAsame levels as those of Q2W. Although timing effect of
CERA administration on serum iron and ferritin levels
must be taken into consideration, decrease of serum iron
and ferritin levels during Q1W may indicate more effect-
ive iron recruitment for erythropoiesis than Q4W.
Although the number of patients on Q1W was very
small, this result suggests that not only Q2W but also
Q1W administration of CERA has a greater erythropoi-
etic effect than Q4W, and Q1W may have more poten-
tial to increase Hb levels than Q2W.
For the production of RBCs, erythropoietin is mandatory,
since otherwise erythroid progenitor cells are rapidly lost to
apoptosis [18]. Although CERA has a longer half-life than
traditional ESAs, our results suggest that 4 weeks as a
CERA administration interval is too long to achieve sus-
tained erythropoiesis, and it is anticipated that the longer
the interval of CERA administration is, the more erythroid
progenitor cells might be lost to apoptosis, resulting in a
decrease in the RBC production rate.
We evaluated the erythropoietic effect of CERA ad-
ministered at different intervals by comparing reticu-
locyte counts and Hb levels. For this purpose, the
CERA dose had to be kept stable during the study
period. But it is sometimes difficult to maintain Hb
levels within the target ranges without changing the
dose of CERA for a substantial period, which meant
that the study period had to be rather short. Espe-
cially when the CERA interval changes, Hb levels
become unstable, and so as the wash-out period of
Fig. 4 Reticulocyte counts and hemoglobin levels when 100 μg of CERA per 4 weeks was administered by Q2W, Q4W, and Q1W
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4 weeks provisionally. As shown in Fig. 5, which illus-
trates the changes of reticulocyte counts and Hb
levels during 100 μg of CERA, as Q4W was missed
(this patient was excluded from evaluation in thisFig. 5 Reticulocyte count and hemoglobin levels in a patient in whom CERstudy), reticulocyte counts decreased to minimal
values at 4 weeks after the administration of CERA
and persisted at the same level until the next admin-
istration of CERA. Although this is just a single
observational datum, this example suggests that theA administration was missed
Daimon et al. Renal Replacement Therapy  (2016) 2:58 Page 7 of 8erythropoietic effect of CERA is not sustained for
more than 4 weeks. This is in accordance with the
reports of reticulocyte dynamics in hemodialysis pa-
tients treated with CERA [15, 19].
To compare the Hb levels of hemodialysis patients
with CERA administered by different intervals, as we re-
ported elsewhere [9], we need to consider the fluctuation
patterns of Hb levels, which differ according to the
CERA interval. Reticulocyte counts were maximal at 7–
10 days of CERA administration and returned to the
same levels by the next monthly CERA administration
[15, 19], which influenced Hb levels. As a result, not
only reticulocyte counts but also Hb levels differ accord-
ing to the timing of the CERA administration and blood-
work, with the timing effect more prominent when
CERA administration intervals are longer. This is also
the case when we evaluate the serum iron, ferritin, or
hepcidin levels which change in a mirror-image manner
to the reticulocyte counts [7, 9, 15, 19].
In this study, Hb levels in the three groups of patients
with CERA at doses of 50, 100, and 150 μg per 4 weeks
were the same, which means that as a whole patients in
the group with smaller dose of CERA have a higher re-
sponsiveness to CERA than patients in the group with a
larger dose. But this “responsiveness” to ESAs is not
equivalent to the “RBC production rate” by ESAs. The
anemia of hemodialysis patients is not exclusively attrib-
utable to hypoproduction of RBCs. In the absence of
considerable blood loss due to hemorrhage or the
hemodialysis procedure itself, Hb levels of hemodialysis
patients are affected by a shortened RBC lifespan. In
healthy adults, the RBC lifespan is about 120 days within
a narrow distribution. On the other hand, it is reported
that in hemodialysis patients, the mean RBC lifespan is
89 days with high interindividual variability [11]. Al-
though the influence of RBC lifespan on Hb levels in
hemodialysis patients is substantial, this factor has been
largely neglected [20]. In hemodialysis patients, RBC life-
span is influenced by the uremic state [21, 22], ESA ad-
ministration [19, 23], and/or inflammation. The higher
levels of CRP and hepcidin and lower levels of iron in
patients receiving CERA 150 μg/4W than in those re-
ceiving 100 or 50 μg/4W may indicate the bluntness of
iron recruitment for erythropoiesis but may also indicate
a shorter RBC lifespan in patients requiring higher doses
of CERA. Also, the highest level of Hb seen during
evaluation 3 as compared to that during evaluation 1
and 2 with the same reticulocyte counts may suggest a
longer RBC lifespan during Q1W of CERA than that
during Q2W and Q4W.
For the effective treatment of anemia in hemodialysis
patients, we need to consider multiple factors such as
iron deficiency, inflammation, hyperparathyroidism, and
dialysis dose and adjust them whenever possible. Alsoour study suggests that by changing the interval of
CERA, the CERA dose can be reduced without exacer-
bating Hb control. Moreover, it is anticipated that the
more sustained erythropoiesis and RBC production asso-
ciated with a shorter interval of CERA can prevent the oc-
currence of Hb overshoot or Hb cycling. Although any
effects of such factors on the mortality of hemodialysis
patients have not been well documented [24], a shorter
interval of CERA administration has advantages in sta-
bilizing Hb levels, reducing the cost of ESAs, and redu-
cing the workload associated with frequent changes of
the ESA dose.
Conclusions
In hemodialysis patients, a shorter interval of CERA ad-
ministration can produce more RBC and increase Hb
levels. To achieve efficient and sustained RBC produc-
tion and maintenance of Hb levels within the narrow
target range, shorter than a 4-week interval of CERA
administration appears preferable.
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